Analysts at Deutsche Bank Reiterate their “Sell” rating for South32 Limited (LON:S32). The Price Target is GBX 170.00; Bluebird Bio (BLUE) SI Decreased By 6.08%

December 7, 2017 - By Louis Casey

The financial firm have set TP of GBX 170.00 on South32 Limited (LON:S32) shares. This is -5.23% from the current stock price. In analysts report issued on Thursday morning, Deutsche Bank kept their “Sell” rating on shares of S32.

Bluebird Bio Incorporated (NASDAQ:BLUE) had a decrease of 6.08% in short interest. BLUE’s SI was 4.26 million shares in December as released by FINRA. Its down 6.08% from 4.54M shares previously. With 697,500 avg volume, 6 days are for Bluebird Bio Incorporated (NASDAQ:BLUE)’s short sellers to cover BLUE’s short positions. The SI to Bluebird Bio Incorporated’s float is 10.53%. The stock decreased 2.00% or $3.25 during the last trading session, reaching $159.4. About 976,497 shares traded or 25.50% up from the average. bluebird bio, Inc. (NASDAQ:BLUE) has risen 112.34% since December 7, 2016 and is uptrending. It has outperformed by 95.64% the S&P500.

Investors sentiment increased to 1.68 in Q2 2017. Its up 0.68, from 1 in 2017Q1. It is positive, as 21 investors sold bluebird bio, Inc. shares while 53 reduced holdings. 50 funds opened positions while 74 raised stakes. 47.91 million shares or 5.30% more from 45.50 million shares in 2017Q1 were reported. First Light Asset Mngmt Ltd Com reported 1.19% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE). Qs Investors Limited Liability reported 1,207 shares. Peregrine Asset Advisers owns 8,390 shares. Brighton Jones Ltd Limited Liability Company, Washington-based fund reported 33,812 shares. First Mercantile Trust holds 0.03% in bluebird bio, Inc. (NASDAQ:BLUE) or 1,409 shares. Trexquant Inv Limited Partnership holds 0.08% or 2,800 shares. Sg Americas Ltd Liability Company has 0% invested in bluebird bio, Inc. (NASDAQ:BLUE). Mirae Asset Glob Invests Company holds 5,643 shares. 9 were reported by Oppenheimer Asset. Winfield Associates Incorporated holds 2,822 shares. Capital Investors holds 1.11 million shares. Tiaa Cref Invest Ltd accumulated 0.02% or 216,219 shares. Natixis Asset stated it has 0.03% in bluebird bio, Inc. (NASDAQ:BLUE). 9,090 were accumulated by Woodstock. Mitsubishi Ufj Tru Corp has invested 0.03% in bluebird bio, Inc. (NASDAQ:BLUE).

Among 24 analysts covering bluebird bio (NASDAQ:BLUE), 15 have Buy rating, 2 Sell and 7 Hold. Therefore 63% are positive. bluebird bio had 69 analyst reports since August 11, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, October 3 by Wells Fargo. The rating was maintained by Barclays Capital with “Overweight” on Thursday, November 2. As per Thursday, November 2, the company rating was maintained by Wedbush. Roth Capital maintained the stock with “Buy” rating in Friday, August 28 report. The firm has “Buy” rating given on Wednesday, November 1 by Leerink Swann. The firm has “Sell” rating by Cantor Fitzgerald given on Monday, July 24. On Tuesday, June 6 the stock rating was upgraded by BMO Capital Markets to “Outperform”. The firm earned “Neutral” rating on Monday, February 6 by Roth Capital. The stock has “Buy” rating by Maxim Group on Friday, June 2. As per Friday, November 3, the company rating was upgraded by Morgan Stanley.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. The company has market cap of $7.31 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. It currently has negative earnings. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications.

The stock decreased 1.51% or GBX 2.75 during the last trading session, reaching GBX 179. About 474,724 shares traded. South32 Limited (LON:S32) has 0.00% since December 7, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 12 analysts covering South32 Limited Ord Npv Di Wi (LON:S32), 5 have Buy rating, 2 Sell and 5 Hold. Therefore 42% are positive. South32 Limited Ord Npv Di Wi has GBX 240 highest and GBX 47 lowest target. GBX 176.42’s average target is -1.44% below currents GBX 179 stock price. South32 Limited Ord Npv Di Wi had 202 analyst reports since July 23, 2015 according to SRatingsIntel. As per Tuesday, October 24, the company rating was maintained by Barclays Capital. Jefferies downgraded South32 Limited (LON:S32) on Thursday, June 8 to “Hold” rating. BNP Paribas maintained South32 Limited (LON:S32) on Wednesday, February 17 with “Outperform” rating. The stock has “Hold” rating by Deutsche Bank on Tuesday, August 9. The stock of South32 Limited (LON:S32) has “Hold” rating given on Friday, October 14 by Jefferies. Liberum Capital maintained South32 Limited (LON:S32) rating on Thursday, February 25. Liberum Capital has “Hold” rating and GBX 90 target. Deutsche Bank maintained it with “Buy” rating and GBX 121 target in Tuesday, August 18 report. The stock of South32 Limited (LON:S32) earned “Sell” rating by Deutsche Bank on Tuesday, November 7. The rating was maintained by Liberum Capital with “Sell” on Monday, November 27. Deutsche Bank maintained the shares of S32 in report on Friday, August 25 with “Hold” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By :